Mark Genovese, MD

Publications

• Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
  Genovese, M. C., Fleischmann, R. M., Greenwald, M., Satterwhite, J., Veenhuizen, M., & Benichou, O. (2013). Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. ANNALS OF THE RHEUMATIC DISEASES, 72(9), 1461-1468.
• Novel small molecule therapeutics in rheumatoid arthritis
  Kelly, V., & Genovese, M. (2013). Novel small molecule therapeutics in rheumatoid arthritis. RHEUMATOLOGY, 52(7), 1155-1162.
• Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
  Genovese, M. C., Rubbert-Roth, A., Smolen, J. S., Kremer, J., Khraishi, M., & van Vollenhoven, R. (2013). Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. JOURNAL OF RHEUMATOLOGY, 40(6), 768-780.
• Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., & Mpofu, S. (2013). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the rheumatic diseases, 72(6), 863-869.
  
• Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., & Genovese, M. C. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. JOURNAL OF RHEUMATOLOGY, 40(5), 579-589.
  
• Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., & Magilavy, D. B. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. JOURNAL OF RHEUMATOLOGY, 40(4), 369-378.
  
• Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., & Sloan-Lancaster, J. (2013). Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 65(4), 880-889.
  
• Effects of sclerostin antibody on healing of a non-critical size femoral bone defect Jawad, M. U., Fritton, K. E., Ma, T., Ren, P.-G., Goodman, S. B., & Genovese, M. C. (2013). Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. JOURNAL OF ORTHOPAEDIC RESEARCH, 31(1), 155-163.
  
• Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Aranda, R., & DougadoS, M. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. JOURNAL OF RHEUMATOLOGY, 39(8), 1546-1554.
  
• Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study Genovese, M. C., Han, C., Keystone, E. C., Hsia, E. C., Buchanan, J., & Rahman, M. U. (2012). Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. JOURNAL OF RHEUMATOLOGY, 39(6), 1185-1191.
  
• Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., & Alten, R. (2011). Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate. ARTHRITIS AND RHEUMATISM, 63(10), 2854-2864.
  
• Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., & Tak, P. P. (2011). Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial. ARTHRITIS AND RHEUMATISM, 63(7), 1793-1803.
  
• A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., & Tong, S. E. (2011). A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 38(5), 846-854.
  
• An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents Genovese, M. C., Kavanaugh, A., Weinblatt, M. E., Peterfy, C., DiCarlo, J., & Magilavy, D. B. (2011). An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents. ARTHRITIS AND RHEUMATISM, 63(2), 337-345.
  
• LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., & Sloan-Lancaster, J. (2010). LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. ARTHRITIS AND RHEUMATISM, 62(4), 929-939.
  
• Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S., Keystone, E., & Shaw, T. M. (2009). Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. ANNALS OF THE RHEUMATIC DISEASES, 68(12), 1894-1897.
  
• First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy Schmajuk, G., & Genovese, M. C. (2009). First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. JOURNAL OF RHEUMATOLOGY, 36(7), 1559-1560.
  
• Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., & Sasso, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(7), 1429-1441.
  
• Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo Ma, T., Ren, P.-G., Larsen, D. M., Suenaga, E., Zilber, S., & Goodman, S. B. (2009). Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 89A(1), 117-123.
  
• Inhibition of p38: Has the Fat Lady Sung Genovese, M. C. (2009). Inhibition of p38: Has the Fat Lady Sung. ARTHRITIS AND RHEUMATISM, 60(2), 317-320.
  
• Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., & Robinson, W. H. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 11(3).
  
• Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., & Gomez-Rein, J. J. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. ARTHRITIS AND RHEUMATISM, 58(10), 2968-2980.
  
• Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Del Giudice, J., Baldassare, A., & Dummer, W. (2008). Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. ARTHRITIS AND RHEUMATISM, 58(9), 2652-2661.
  
• Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., & Dougados, M. (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. ANNALS OF THE RHEUMATIC DISEASES, 67(4), 547-554.
  
• Efficacy results from pivotal clinical trials with abatacept Rozelle, A. L., & Genovese, M. C. (2007). Efficacy results from pivotal clinical trials with abatacept. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25(5), S30-S34.
  
• A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323-1327.
  
• A pilot trial of rituximab in the treatment of patients with dermatomyositis Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763-767.
  
• Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines Hueber, W., Tomooka, B. H., Zhao, X., Kidd, B. A., Drijfhout, J. W., & Robinson, W. H. (2007). Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 66(6), 712-719.
  
• Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy Genovese, M. C., Mease, P. J., Thomson, G. Td., Kivitz, A. J., Perdok, R. J., & Sasso, E. H. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. JOURNAL OF RHEUMATOLOGY, 34(5), 1040-1050.
  
• Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., & Robinson, W. H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. JOURNAL OF CLINICAL INVESTIGATION, 116(10), 2633-2642.
  
• A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., & Kavanaugh, A. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 32(12), 2345-2350.
  
• Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Magnano, M. D., & Genovese, M. C. (2005). Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Current rheumatology reports, 7(5), 407-415.
  
• Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition Genovese, M. C., Becker, J., Schiff, M., Luggen, M., Sherrer, Y., & Dougados, M. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEW ENGLAND JOURNAL OF MEDICINE, 353(11), 1114-1123.
  
• Antigen microarray profiling of autoantibodies in rheumatoid arthritis Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., & Robinson, W. H. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), 2645-2655.
  
• Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., & Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 32(7), 1232-1242.
  
• Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 192(6), 1897-1904.
  
• Biologic therapies in clinical development for the treatment of rheumatoid arthritis Genovese, M. C. (2005). Biologic therapies in clinical development for the treatment of rheumatoid arthritis. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 11(3), S45-S54.
  
• Temporal effects of a COX-2-selective NSAID on bone ingrowth Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 72A(3), 279-287.
  
• Pharmacologic modulation of periprosthetic osteolysis Goodman, S. B., Trindade, M., Ma, T., Genovese, M., & Smith, R. L. (2005). Pharmacologic modulation of periprosthetic osteolysis. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, (430), 39-45.
  
• Associations between rheumatoid arthritis and malignancy Chakravarty, E. F., & Genovese, M. C. (2004). Associations between rheumatoid arthritis and malignancy. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 271-?.
  
• Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., & Bekker, P. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. ARTHRITIS AND RHEUMATISM, 50(5), 1412-1419.
  
• Treatment of rheumatoid arthritis with etanercept Genovese, M. C., & Kremer, J. M. (2004). Treatment of rheumatoid arthritis with etanercept. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 311-?.
  
• Unlocking the "PAD" lock on rheumatoid arthritis Utz, P. J., Genovese, M. C., & Robinson, W. H. (2004). Unlocking the "PAD" lock on rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 63(4), 330-332.
  
• A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis research & therapy, 6(1), R73-R77.
  
• Interleukin 1 receptor antagonist inhibits localized bone formation in vivo Ma, T., Miyanishi, K., Trindade, M. Cd., Genovese, M., Regula, D., & Goodman, S. B. (2003). Interleukin 1 receptor antagonist inhibits localized bone formation in vivo. JOURNAL OF RHEUMATOLOGY, 30(12), 2547-2552.
  
• COX-2 selective inhibitors and bone Goodman, S. B., Ma, T., Genovese, M., & Smith, R. L. (2003). COX-2 selective inhibitors and bone. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 16(3), 201-205.
  
• Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., & Lang, P. (2003). Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING, 18(1), 66-71.
  
• Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., & Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 65A(1), 43-50.
  
• Rheumatic syndromes associated with malignancy Chakravarty, E., & Genovese, M. C. (2003). Rheumatic syndromes associated with malignancy. CURRENT OPINION IN RHEUMATOLOGY, 15(1), 35-43.
  
• COX-2 selective NSAID decreases bone ingrowth in vivo Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., & Smith, R. L. (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. JOURNAL OF ORTHOPAEDIC RESEARCH, 20(6), 1164-1169.
  
• Central nervous system lupus and pregnancy: 11-year experience at a single center. El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., & Druzin, M. L. (2002). Central nervous system lupus and pregnancy: 11-year experience at a single center. journal of maternal-fetal & neonatal medicine , 12(2), 99-103.
  
• Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., & Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. ARTHRITIS AND RHEUMATISM, 46(6), 1443-1450.
  
• Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis Genovese, M. C., Uhrin, Z., Bloch, D. A., Oehlert, J., Sibley, R. K., & Strober, S. (2002). Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. ARTHRITIS AND RHEUMATISM, 46(4), 1014-1018.
  
• Autoantigen microarrays for multiplex characterization of autoantibody responses Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., & Utz, P. J. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. NATURE MEDICINE, 8(3), 295-301.
  
• Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes Kunkel, E. J., Boisvert, J., Murphy, K., Vierra, M. A., Genovese, M. C., & Campbell, J. J. (2002). Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. AMERICAN JOURNAL OF PATHOLOGY, 160(1), 347-355.
  
• Rules of chemokine receptor association with T cell polarization in vivo Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., & BUTCHER, E. C. (2001). Rules of chemokine receptor association with T cell polarization in vivo. JOURNAL OF CLINICAL INVESTIGATION, 108(9), 1331-1339.
  
• Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. ARTHRITIS AND RHEUMATISM, 44(9), 1977-1983.
  
• Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival Uhrin, Z., Wang, B. We., Matsuda, Y., Strober, S., & Genovese, M. C. (2001). Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival. ARTHRITIS AND RHEUMATISM, 44(7), 1525-1528.
  
• Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., & BUTCHER, E. C. (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. JOURNAL OF CLINICAL INVESTIGATION, 107(5), 595-601.
  
• Current management of rheumatoid arthritis Genovese, M. C., & Davis, J. S. (2001). Current management of rheumatoid arthritis. HOSPITAL PRACTICE, 36(2), 21-?.
  
• A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Pan, J., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., & Soler, D. (2000). A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Journal of immunology , 165(6), 2943-2949.
  
• Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity Kunkel, E. J., Campbell, J. J., Haraldsen, G., Pan, J. L., Boisvert, J., & Agace, W. W. (2000). Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. JOURNAL OF EXPERIMENTAL MEDICINE, 192(5), 761-767.
  
• Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment Genovese, M. C. (1998). Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment. POSTGRADUATE MEDICINE, 103(2), 125-?.
  
• Fever, rash, and arthritis in a woman with silicone gel breast implants Genovese, M. C. (1997). Fever, rash, and arthritis in a woman with silicone gel breast implants. WESTERN JOURNAL OF MEDICINE, 167(3), 149-158.
  
• Lemierre's syndrome Lee, B. K., LOPEZ, F., Genovese, M., & Loutit, J. S. (1997). Lemierre's syndrome. SOUTHERN MEDICAL JOURNAL, 90(6), 640-643.